Prevalence of antibiotic resistance in US hospitals

Diagnostic Microbiology and Infectious Disease

Volumn 78, Issue 3, 2014, Pages 255-262

  Edelsberg, John ^a   Weycker, Derek ^a   Barron, Rich ^b   Li, Xiaoyan ^b   Wu, Hongsheng ^a,c   Oster, Gerry ^a   Badre, Sejal ^b   Langeberg, Wendy J ^b   Weber, David J ^d  

^a POLICY ANALYSIS INC PAI   (United States)

^b AMGEN INC   (United States)

^c WENTWORTH INSTITUTE OF TECHNOLOGY   (United States)

^d IL   (United States)

Author keywords

Antibiotics; Bacterial; Drug resistance

Indexed keywords

ANTIBIOTICS; BACTERIAL; DRUG RESISTANCE;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; UNITED STATES; YOUNG ADULT;

EID: 84893811813     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.11.011     Document Type: Article

References (22)

1. Alliance for the Prudent Use of Antibiotics (APUA). APUA Clinical Newsletter Vol. 30 No. 1, 2012 APUA.
2. Carmeli Y., Eliopoulos G., Mozaffari E., Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002, 162:2223-2228.
3. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing-sixteenth informational supplement (M100-S18) 2008, CLSI, Wayne, PA.
4. Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
5. Farrell D.J., Mendes R.E., Ross J.E., Jones R.N. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis 2009, 65:392-403.
6. Fridkin S.K., Hageman J.C., Morrison M., et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352(14):1436-1444.
7. Garcia M.S., De la Torre M.A., Morales G., et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010, 303:2260-2264.
8. Hidron A.I., Edwards J.R., Patel J., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011.
9. Jones R.N., Kohno S., Ono Y., et al. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis 2009, 64:191-201.
10. Klevens R.M., Morrison M.A., Nadle J., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763-1771.
11. Lautenbach E., Synnestvedt M., Weiner M.G., et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 2009, 30:1186-1192.
12. Marr J.J., Moffet H.L., Kunin C.M. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America. J Infect Dis 1988, 157:869-876.
13. Master R.N., Clark R.B., Karlowsky J.A., et al. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009. Int J Antimicrob Agents 2011, 38:291-295.
14. Moran G.J., Krishnadasan A., Gorwitz R.J., et al. Methicillin-resistant S. Aureus infections among patients in the emergency department. N Engl J Med 2006, 355(7):666-674.
15. Mulvey M.M., Simor A.E. Antimicrobial resistance in hospitals: how concerned should we be?. CMAJ 2009, 180:408-415.
16. Nelson R. Antibiotic development pipeline runs dry. Lancet 2003, 362:1726-1727.
17. Sader H.S., Moet G.J., Farrell D.J., Jones R.N. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers. Diagn Microbiol Infect Dis 2011, 70:412-416.
18. Sanchez G.V., Master R.N., Karlowsky J.A., Bordon J.M. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012, 56:2181-2183.
19. Shlaes D.M., Gerding D.N., John J.F., et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997, 18:275-291.
20. Shorr A.F. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 2009, 37:1463-1469.
21. Sievert D.M., Ricks P., Edwards J.R., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013, 34:1-14.
22. US Department of Health and Human Services. Code of Federal Regulations: Title 45, public welfare; Part 46, protection of human subjects [Web site]. Cited 2009 July 14. Available. http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html.